跳至主要内容
临床试验/NCT06943482
NCT06943482尚未招募4 期

A Pilot Open-label Randomised Trial Comparing the Effectiveness of Steroids and Methotrexate for the Treatment of Idiopathic Granulomatous Mastitis

National University Hospital, Singapore1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年7月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
尚未招募
入组人数
40
试验地点
1
主要终点
Proportion of patients who achieved clinical or radiological complete response by 6 months

研究概览

简要总结

This research study is to determine the effectiveness of prednisolone and methotrexate for IGM patients over a period of one year, in terms of clinical and radiological response. Recruitment will be conducted in National University Hospital (NUH) for patients diagnosed with IGM.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women, aged between 21 and 60 years
  • Positive diagnosis of idiopathic granulomatous mastitis based on histopathology results
  • Willing and able to give informed consent
  • Exclusion Criteria (Patients who meet any of the following prerequisites will not be allowed to take part in this study):
  • Women who are currently pregnant or breastfeeding
  • Cognitive impairment which prevents the patient from giving voluntary consent
  • History of any psychiatric conditions such as depression, psychosis, schizophrenia etc.
  • History of cancer in the past 5 years
  • History of abnormal renal or liver function
  • History of diabetes mellitus
  • History of pulmonary lung disease, pneumonitis, or related conditions
  • Hepatitis B and/or Hepatitis C carrier
  • Diagnosed with tuberculosis (Positive microbiological evaluation for Grocott Methenamine Silver stain and Ziehl- Neelsen stain)
  • Any immunosuppressants or anti-inflammatory medications such as NSAIDS for the past 3 months
  • Concomitant medication that may have contraindication with prednisolone and methotrexate use
  • Hypersensitivity to components or drug products of prednisolone and methotrexate
  • Vaccination with live virus vaccines prior to or during treatment

排除标准

  • 未提供

研究组 & 干预措施

Steroid

Active Comparator

干预措施: Prednisolone (Drug)

Steroid

Active Comparator

干预措施: Omeprazole 20 mg (Drug)

Methotrexate

Experimental

干预措施: Methotrexate (Drug)

Methotrexate

Experimental

干预措施: Folic Acid 5 MG (Drug)

结局指标

主要结局

Proportion of patients who achieved clinical or radiological complete response by 6 months

时间窗: 6 months

Time to clinical response and time to radiological response

时间窗: 6 months

Proportion of patients with relapse in a year within affected breast between each arm.

时间窗: 1 year

次要结局

  • Evaluation of side effects.(1 year)
  • Evaluation of of treatment failure (TF) rate(6 months)
  • Evaluation of frequency of percutaneous or surgical intervention required(6 months)
  • Evaluation of potential unique pattern of gene expression that can be used to diagnose IGM and predict treatment response(3 years)
  • Evaluation of potential biomarkers that may predict response to treatment: eg IL-6, CRP and neutrophil to lymphocyte ratio (NLR)(3 years)
  • Evaluation of patient reported outcome measures(3 years)
  • Validate survey instrument for IGM patients(3 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验